[A21-136] Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to <18 years of age) - Benefit assessment according to §35a Social Code Book V
Last updated 17.01.2022
Project no.:
A21-136
Commission:
Commission awarded on 15.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Chronic hepatitis C in adolescents aged 12 to < 18 years
Result of dossier assessment:
- Genotype 1, 4, 5 or 6: added benefit not proven.
- Genotype 2 or 3: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.